Description
Mva-209-fsp is an experimental vaccine being studied in clinical trials, specifically for certain types of colorectal cancer. It is designed to work alongside another immunotherapy drug called pembrolizumab (Keytruda®). This vaccine is being tested in patients whose tumors are MSI-H (microsatellite instability-high) or dMMR (deficient mismatch repair). These types of tumors have specific genetic characteristics that may make them more responsive to immunotherapy. The vaccine is given as a series of boosts after an initial prime dose of a related vaccine (GAd20-209-fsp). The goal is to stimulate the patient's immune system to recognize and attack the cancer cells. It is currently being studied in Phase 1 and Phase 2 trials.
Mechanism of Action
Mva-209-fsp is a genetic vaccine. It contains genetic material (DNA) that codes for specific proteins, called neoantigens, found on the surface of the patient's cancer cells. The vaccine is designed to teach the patient's immune system to recognize these cancer-specific proteins. By presenting these neoantigens, the vaccine aims to activate immune cells (like T cells) to target and destroy the cancer cells. It is used in combination with pembrolizumab, which is an immunotherapy drug that blocks a protein called PD-1, helping to further boost the immune response against the cancer.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.